JP2007534634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007534634A5 JP2007534634A5 JP2006539166A JP2006539166A JP2007534634A5 JP 2007534634 A5 JP2007534634 A5 JP 2007534634A5 JP 2006539166 A JP2006539166 A JP 2006539166A JP 2006539166 A JP2006539166 A JP 2006539166A JP 2007534634 A5 JP2007534634 A5 JP 2007534634A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- tegafur
- antitumor
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- 230000000259 anti-tumor effect Effects 0.000 claims 20
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims 14
- 229960001674 tegafur Drugs 0.000 claims 14
- 235000020937 fasting conditions Nutrition 0.000 claims 12
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 claims 11
- 229950000193 oteracil Drugs 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 claims 9
- 229940123171 Dihydropyrimidine dehydrogenase inhibitor Drugs 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 206010059024 Gastrointestinal toxicity Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims 3
- 235000012054 meals Nutrition 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229930192392 Mitomycin Natural products 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940120638 avastin Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56618004P | 2004-04-29 | 2004-04-29 | |
| US60/566,180 | 2004-04-29 | ||
| PCT/JP2005/008450 WO2005105086A1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007534634A JP2007534634A (ja) | 2007-11-29 |
| JP2007534634A5 true JP2007534634A5 (https=) | 2008-05-08 |
| JP5376758B2 JP5376758B2 (ja) | 2013-12-25 |
Family
ID=35241420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539166A Expired - Fee Related JP5376758B2 (ja) | 2004-04-29 | 2005-04-27 | テガフールの投与に起因する消化器毒性を軽減する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080166427A1 (https=) |
| EP (1) | EP1750703B1 (https=) |
| JP (1) | JP5376758B2 (https=) |
| AT (1) | ATE540679T1 (https=) |
| AU (1) | AU2005237364B2 (https=) |
| CY (2) | CY1112451T1 (https=) |
| DK (1) | DK1750703T3 (https=) |
| ES (1) | ES2378072T3 (https=) |
| HR (1) | HRP20120293T1 (https=) |
| ME (1) | ME01335B (https=) |
| PL (1) | PL1750703T3 (https=) |
| PT (1) | PT1750703E (https=) |
| RS (1) | RS52217B (https=) |
| RU (1) | RU2348409C2 (https=) |
| SI (1) | SI1750703T1 (https=) |
| WO (1) | WO2005105086A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010131769A1 (en) * | 2009-05-13 | 2010-11-18 | Taiho Pharmaceutical Co., Ltd. | Treatment of diffuse-type gastric cancers using s-1 and cisplatin |
| CN102648412A (zh) * | 2009-07-17 | 2012-08-22 | 美瑞德生物工程公司 | 5-fu的检测方法 |
| WO2011022174A1 (en) * | 2009-08-21 | 2011-02-24 | Myriad Genetics, Inc. | Method of processing blood samples containing 5-fu |
| EP2422784A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422848A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422815A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| WO2015134837A2 (en) * | 2014-03-06 | 2015-09-11 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| CA2944088C (en) * | 2014-03-28 | 2022-06-21 | L-Nutra Inc. | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| EP3290038A4 (en) * | 2015-04-30 | 2018-12-26 | Taiho Pharmaceutical Co., Ltd. | Agent for alleviating adverse reaction to antitumor drug |
| JP6439761B2 (ja) * | 2016-08-09 | 2018-12-19 | トヨタ自動車株式会社 | ＮＯｘ吸蔵還元触媒の製造方法 |
| CN106619689B (zh) * | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| US20250186435A1 (en) * | 2020-05-19 | 2025-06-12 | Cellix Bio Private Limited | Pharmaceutical formulations and their preparations for treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635946A (en) * | 1969-07-22 | 1972-01-18 | Solomon Aronovich Giller | N1-(2'-furanidyl)-derivatives of 5-substituted uracils |
| EP0180188B1 (en) * | 1984-10-30 | 1992-04-15 | Otsuka Pharmaceutical Co., Ltd. | A composition for increasing the anti-cancer activity of an anti-cancer compound |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| NL194430C (nl) * | 1989-01-05 | 2002-04-04 | Otsuka Pharma Co Ltd | Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking. |
| WO1992021345A1 (en) * | 1991-05-27 | 1992-12-10 | Taiho Pharmaceutical Co., Ltd. | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| RU2198171C2 (ru) * | 1998-10-12 | 2003-02-10 | Леонидов Николай Борисович | Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием |
-
2005
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es not_active Expired - Lifetime
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 RS RS20120127A patent/RS52217B/sr unknown
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
- 2005-04-27 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en not_active Ceased
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en not_active Expired - Lifetime
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
-
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I2/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1849470T3 (en) | Anticancer drug containing ALPHA, ALPHA, ALPHA-TRIFLUORTHYMIDINE and THYMIDINPHOSPHORYLASE INHIBITOR | |
| JP2006515883A5 (https=) | ||
| JP2007534634A5 (https=) | ||
| JP2010525050A5 (https=) | ||
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2012506448A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| JP2012509889A5 (https=) | ||
| JP2013503174A5 (https=) | ||
| CN1972676A (zh) | 用于个体化应答式给药方案的营养药的组合物和系统 | |
| JP2011502997A5 (https=) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| ME01335B (me) | Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura | |
| CN110123771A (zh) | 药物组合药物 | |
| CN102648279B (zh) | 用于治疗药物诱发的手足综合征的组合物与方法 | |
| CN102924456B (zh) | 当以乳清酸盐衍生物给药时降低甲氨蝶呤副作用和毒性的组合物和方法 | |
| KR100812693B1 (ko) | 항종양 효과 증강제 및 항종양제 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| JP7822619B2 (ja) | 胆管癌の処置のためのパノビノスタットを含む併用療法 | |
| JP2006514063A5 (https=) | ||
| CN1330308C (zh) | 含有4－吡啶基甲基酞嗪的联合产品及其应用 | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| WO2014157443A1 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| US20240122937A1 (en) | Treating cancer in patient with pten inactivating mutation |